[
    [
        {
            "time": "2018-01-02",
            "original_text": "衡量公司真实盈利能力 净现比才是A股的“照妖镜”",
            "features": {
                "keywords": [
                    "净现比",
                    "盈利能力",
                    "A股"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "衡量公司真实盈利能力 净现比才是A股的“照妖镜”",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-03",
            "original_text": "2018年全球医疗机器人行业发展前景广阔 亚洲市场或将成为转移重心",
            "features": {
                "keywords": [
                    "医疗机器人",
                    "亚洲市场",
                    "发展前景"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗设备"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "2018年全球医疗机器人行业发展前景广阔 亚洲市场或将成为转移重心",
                "Correlation": 3,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 1,
                "Market_Scope": 9,
                "Time_Proximity": 4,
                "Headline_Structure": 6,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-01-04",
            "original_text": "医药生物：首个国产生物类似药获批释放积极信号",
            "features": {
                "keywords": [
                    "生物类似药",
                    "获批",
                    "医药生物"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物：首个国产生物类似药获批释放积极信号",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-05",
            "original_text": "融资买入额激增 生物医药板块补涨",
            "features": {
                "keywords": [
                    "融资买入额",
                    "生物医药",
                    "补涨"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "融资买入额激增 生物医药板块补涨",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-06",
            "original_text": "复星医药分拆复宏汉霖冲刺港股IPO 上市前夕首个国产生物类似药获批",
            "features": {
                "keywords": [
                    "复星医药",
                    "复宏汉霖",
                    "港股IPO",
                    "生物类似药",
                    "获批"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药分拆复宏汉霖冲刺港股IPO 上市前夕首个国产生物类似药获批",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-07",
            "original_text": "复星医药:中国首个生物类似药获批,验证公司研发实力",
            "features": {
                "keywords": [
                    "复星医药",
                    "生物类似药",
                    "研发实力"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药:中国首个生物类似药获批,验证公司研发实力",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]